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Metformin, developed from an ancient herbal remedy, remains the front-line drug for treatment of type 2 dia-
betes. Several targets to account for its therapeutic effects have been proposed, but a recent paper suggests
a novelmechanism in which it antagonizes the cyclic AMP-dependent effects of glucagon on hepatic glucose
production.Metformin and the related drug phenfor-
min are biguanides, derivatives of guani-
dine (Figure 1A). Guanidine and its
naturally occurring isoprenyl derivative,
galegine, were identified in the early twen-
tieth century as pharmacologically active
components of the medicinal herbGalega
officinalis (French Lilac or Goat’s Rue),
which had been used in Europe to treat
various maladies, including ‘‘thirst and
frequent urination.’’ Metformin and phen-
formin were synthesized in the 1920s
and shown to have hypoglycemic effects
in animals, and galegine was even tested
in humans (Muller and Reinwein, 1927).
However, the success of insulin therapy
seemed to put further studies of these
compounds on hold until the 1960s, by
which time the distinction between types
1 and 2 diabetes had been made, and
the biguanides were introduced for treat-
ment of the latter. Phenformin was subse-
quently withdrawn in most countries due
to the rare but life-threatening side effect
of lactic acidosis, but metformin has
gone from strength to strength and is
now usually the first-choice drug treat-
ment. There have been several proposals
to explain its mechanism of action, and
a recent letter to Nature (Miller et al.,
2013) has suggested yet another.
The biguanides appear to act partly by
enhancing insulin sensitivity and partly
by inhibiting hepatic glucose production.
The first clue to how they might act at
the molecular level came with findings
that, driven due to their positive charge
by the electrical potential across the inner
membrane, they accumulate in mitochon-
dria where they inhibit complex I of the
respiratory chain (El-Mir et al., 2000;
Owen et al., 2000). This would explain
the occurrence of lactic acidosis if inhibi-
tion became severe, but even mild inhibi-
tion of the respiratory chain would lowercellular ATP and cause increases in ADP
and AMP (the latter due to the adenylate
kinase reaction). The biguanides would
therefore be expected to activate AMP-
activated protein kinase (AMPK), which
was indeed demonstrated (Zhou et al.,
2001). It had already been proposed that
AMPK-activating drugs might be effective
for treatment of type 2 diabetes (Winder
and Hardie, 1999), and the AMPK-acti-
vating nucleoside AICAR (which is taken
up by cells and converted to the AMP
mimetic, ZMP) had been reported to
inhibit expression of gluconeogenic
enzymes in liver cells (Lochhead et al.,
2000). From these results, it seemed likely
that AMPK was the molecular target of
the biguanides. However, doubts about
AMPK being their sole target were raised
when it was found that the acute effects
of metformin on glucose tolerance were
essentially normal in mice lacking both
AMPK catalytic subunits in liver, and
that metformin still depressed glucose
production acutely in AMPK-null hepato-
cytes (Foretz et al., 2010).
The hormone glucagon, released in
response to fasting or starvation and
acting via cyclic AMP (cAMP) and PKA
(cAMP-dependent protein kinase), pro-
motes hepatic glucose production by
inhibiting glycolysis and activating gluco-
neogenesis, both acutely and by longer-
term effects on gene expression. In the
new study, Miller et al. (2013) show that
biguanides rapidly reduce cAMP levels
induced by glucagon in primary hepato-
cytes, and reduced phosphorylation of
PKA substrates, including the 6-phospho-
fructo-2-kinase isoform PFKFB1. Phos-
phorylation of PFKFB1 by PKA inhibits
the formation of fructose-2,6-bisphos-
phate, an intracellular mediator that
acutely activates the glycolytic enzyme
6-phosphofructo-1-kinase and inhibitsCell Metabolismthe gluconeogenic enzyme fructose-1,6-
bisphosphatase; phosphorylation of other
PKA targets promotes expression of
gluconeogenic enzymes. Lowering of
cAMP would therefore inhibit the switch
from glycolysis to gluconeogenesis trig-
gered by glucagon. Although the bigua-
nides activated AMPK as expected, this
was not required for their cAMP-lowering
effects, which were still apparent even in
AMPK-null hepatocytes. Biguanides had
no effect on the actions of the cell perme-
able cAMP analog SP-8Br-cAMPS-AM
(which bypasses adenylate cyclase), but
still inhibited increases in cAMP induced
by phosphodiesterase inhibitors, sug-
gesting that adenylate cyclase might be
their point of action. In fact, it had been
reported nearly 40 years ago that AMP
inhibits adenylate cyclase (Blume and
Foster, 1975), although the physiological
or pharmacological relevance of that
finding had remained unclear. Miller
et al. (2013) showed that treatment of
insulin-resistant mice with oral metformin
activated hepatic AMPK (being used
here as a biomarker of cellular AMP
levels) but also reduced cAMP, phos-
phorylation of PKA targets including
PFKFB1, and blood glucose. Intraperito-
neal injection of glucagon also increased
blood glucose in metformin-treated
animals, although not to the levels seen
in untreated controls.
These results do indeed suggest that
the mechanism they propose for metfor-
min action—involving inhibition of
glucagon action on adenylate cyclase by
AMP (Figure 1B)—was operating in vivo,
and represents one of the AMPK-inde-
pendent mechanisms by which bigua-
nides acutely inhibit glucose production.
They also found that AICAR lowered
cAMP in AMPK-null hepatocytes, which
would be expected if ZMP, like AMP,17, March 5, 2013 ª2013 Elsevier Inc. 313
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Figure 1. Structures of Metformin, Phenformin, Guanidine, and Galegine; and Schematic
Diagram of the Proposed New Mechanism by which Metformin Inhibits Hepatic
Gluconeogenesis
(A) The structures of guanidine-based drugs; metformin and phenformin are biguanides, whereas galegine
is an isoprenyl derivative of guanidine.
(B) Up or down arrows next to a metabolite or enzyme show the direction the concentration or activity
changes in response to biguanide. Metformin or phenformin (whose uptake into hepatocytes is promoted
by the organic cation transporter, OCT1) accumulate in mitochondria where they inhibit complex 1 of the
respiratory chain, lowering cytoplasmic ATP and increasing ADP and AMP. AMP activates AMPK but also
inhibits adenylate cyclase, reducing effects of glucagon on cAMP and PKA and thus reducing the ability of
PKA to promote gluconeogenesis by phosphorylation of PFKFB1 and other targets regulating transcrip-
tion of gluconeogenic genes. KEY: F16BP, fructose-1,6-bisphosphate; F26BP, fructose-2,6-bisphos-
phate; F16BPase, fructose-1,6-bisphosphatase; G6Pase, glucose-6-phosphatase; GLUT2, glucose
transporter-2.
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Previewsinhibited adenylate cyclase. Although
inhibition of adenylate cyclase by ZMP
was not directly demonstrated, if correct
it could explain the antidiabetic effects
of AICAR observed in animal models.
The results also emphasize the general
point that effects of increasing cellular
AMP are always likely to be mediated by
multiple mechanisms, and not simply by
activation of AMPK. Indeed, another314 Cell Metabolism 17, March 5, 2013 ª201mechanism by which AMP (and ZMP)
might acutely inhibit gluconeogenesis
is by direct inhibition of fructose-1,6-
bisphosphatase (Vincent et al., 1991).
There are one or two caveats in assess-
ing the implications of these results. One
beneficial feature of metformin use is
that it does not carry any risk of inducing
hypoglycemia, which is hard to explain if
inhibition of adenylate cyclase is its only3 Elsevier Inc.mechanism of action. The stimulatory
effect of glucagon on hepatic glucose
production is thought to ensure that blood
glucose levels are maintained during fast-
ing, so if metformin worked simply by
opposing this effect you might imagine
that its use would lead to hypoglycemic
episodes. Another caveat is that the in vivo
experiments were quite short term (up to
2.5 hr), and do not rule out the possibility
that AMPK activation might be respon-
sible for longer-term enhancements in
insulin sensitivity induced by metformin.
This might arise through AMPK causing
a switch from synthesis to oxidation of
fat, thus reducing the elevated storage
of triglycerides in liver and muscle that is
often associated with insulin-resistant
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